Crossmark

Novel Pyridazine-3(2H)-one Derivatives as SARS-CoV-2 Inhibitors: Design, Synthesis, Characterization, Molecular Docking, and Their In Silico ADMET Studies

Crossref DOI link: https://doi.org/10.1134/S1068162024060086

Published Online: 2024-12-16

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rabara, Kilol M.

Lalpara, Jaydeep N.

Dubal, Gaurang G.
License Information

Text and Data Mining valid from 2024-12-01

Version of Record valid from 2024-12-01
More Information

Article History

Received: 8 March 2024

Revised: 21 March 2024

Accepted: 22 March 2024

First Online: 16 December 2024

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

: This article does not contain any studies involving patients or animals as test objects.

: Informed consent was not required for this article. No conflict of interest was declared by the authors.

Document is current

Any future updates will be listed below